Senseonics reported record Q3 revenue and raised full-year guidance, while the stock rose 2.3%—a roughly flat reaction. The quarter showed accelerating commercial adoption, though the transcript also places significant future growth hopes on upcoming pump integrations and the Freedom development program.
The stock gained 7.6% post-earnings, reflecting investor approval of revenue growth, margin expansion, and upward guidance. Strong execution on commercial integration and new market penetration appear to have outweighed any lingering skeptics.
Senseonics reported a robust 90% year-over-year revenue growth in Q3 2025, driven by surging demand for its Eversense 365 continuous glucose monitor and enhanced direct-to-consumer marketing initiatives.